CONTENTS
Assistant Editor
Special Assignments
julia aalbers
Tel: 021 976 4378
Fax: 086 610 3395
e-mail:
Production Editor
SHAUNA GERMISHUIZEN
Tel: 021 785 7178
Fax: 086 628 1197
e-mail:
Editorial Assistant &
Circulation
ELSABÉ BURMEISTER
Tel: 021 976 8129
e-mail:
Production
Co-ordinator
WENDY WEGENER
Tel: (021) 976-4378
e-mail:
GAUTENG CONTRIBUTOR
PETER WAGENAAR
Cell 082 413 9954
e-mail :
Editorial BOARD
The
Cardiovascular Journal of Africa
,
incorporating the
Cardiovascular
Journal of South Africa
, is published six
times a year, the deemed publication
date being the seventh day of the
second designated month,
i.e. 7 February, 7 April, 7 June, 7
August and 7 October.
Copyright:
Clinics Cardive Publishing, Pty, Ltd.
Layout:
Martingraphix
Printer:
Durbanville Commercial Printers
All submissions to CVJA are to be
made online via
Electronic submission by means of an
e-mail attachment may be considered
under exceptional circumstances.
Postal address: PO Box 1013,
Durbanville, 7551
Tel/Fax: 021 976 8129
Int.: +27 21 976 8129
e-mail:
Electronic abstracts available on
Pubmed
Audited circulation
Full text articles available on:
or via
co.za; for access codes contact
User ID: cvja8
Password: cvja8
Subscriptions for six issues:
South Africa: R300 (excl VAT)
Other African countries: $30
Overseas: Institutions: R845 ($82)
Individuals: R1 080 ($105)
The views and opinions expressed
in the articles and reviews published
are those of the authors and do not
necessarily reflect those of the editors
of the Journal or its sponsors. In all
clinical instances, medical practitioners
are referred to the product insert
documentation as approved by the
relevant control authorities.
VOL 21, NO 2. MARCH / APRIL 2010
Case Reports
109 Amiodarone-induced QT prolongation in a newly transplanted heart associated with
recurrent ventricular fibrillation
ER Schwarz • LS Czer • SA Simsir • RM Kass • A Trento
113 The unicuspid aortic valve
SM Yuan • H Jing • J Lavee
Drug Trends
115 Focus on the American College of Cardiology Congress, 2010
Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/
perindopril combination to reduce stroke risk
Comparison of ivabradine plus
β
-blockers versus β-blocker therapy only
INVEST study warns on too-low BP in diabetic patients with CAD
ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to
therapy of dyslipidaemic type 2 diabetic patients
120 Combination therapy in hypertension: new recommendations
123 The use of anticoagulants for venous thrombo-embolism
124 Opinions in hypertension management:
Angiotensin receptor blockers in hypertension patients: earlier use of these better-
tolerated medications is warranted
Supplement
International Symposium:
Integrated Approach to Disease Management:
Endocrinology, Metabolic Disorders and
Cardiac Consequences
Cape Town, 6–7 March 2010
Abstracts of the 7th Scientific Congress of the
Cameroon Cardiac Society (CCS)
17–19 March 2010, Yaoundé, Cameroon,
published electronically
It's the
shell that
makes
safer.
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
